



#41

0350

#4

Attorney Docket No. 08841.105024

~~0350~~
~~0300~~

#4

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: L. J. Stuyver *et al.*

Serial No.: 10/045,292

Filed: October 18, 2001

Title: Modified Nucleosides for the Treatment of Viral Infections
and Abnormal Cellular Proliferation

Assistant Commissioner for Patents
Washington, DC 20231

March 14, 2002


Transmittal of Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,



Josephine Young
Reg. No. 48,308

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-3170 (Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Josephine Young
Reg. No. 48,308

Date: March 14, 2002

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO			<div style="border: 1px solid black; border-radius: 50%; padding: 5px; display: inline-block;"> MAR 21 2002 1048 1048 </div>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/045,292	
			Filing Date	18 October 2001	
			First Named Inventor	Stuyver, L.J. et al	
			Group Art Unit		
			Attorney Docket Number	08841.105024	
Sheet	1	of	3		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
/ AA	AA	ALI <i>et al.</i> , <u>Tetrahedron Letters</u> , 1990, 31, 1509, Pergamon Press, Great Britain.		
/ AB	AB	CHU <i>et al.</i> , <u>J. Heterocycl. Chem.</u> , 1980, 17, 1435.		
/ AC	AC	DUSCHINSKY <i>et al.</i> , <u>J. Med. Chem.</u> , 1967, 10, 47.		
/ AD	AD	HUANG, G.-F. <i>et al.</i> <u>J. Carbohyd. Nucleosides Nucleotides</u> , 1978, 5, 317.		
/ AE	AE	IKEHARA, M. <i>et al.</i> <u>Chem. Pharm. Bull.</u> , 1967, 15, 94.		
/ AF	AF	KABAT <i>et al.</i> , <u>J. Med. Chem.</u> , 1987, 30, 924.		
/ AG	AG	KANEKO, M. <i>et al.</i> <u>Chem. Pharm. Bull.</u> 1972, 20, 635.		
/ AH	AH	KAZIMIERCZUK, Z. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1984, 106, 6379.		
/ AI	AI	LEE, W. W. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1961, 83, 1906.		
/ AJ	AJ	LIN, T. S. <i>et al.</i> <u>J. Med. Chem.</u> , 1991, 34, 693.		
/ AK	AK	LOHMANN, V. <i>et al.</i> <u>Virology</u> , 108, 1998, Academic Press.		
/ AL	AL	MARUMOTO, R. <i>et al.</i> <u>Chem. Pharm. Bull.</u> 1974, 22, 128.		
/ AM	AM	MENDEZ, E. <i>et al.</i> <u>J. Virol.</u> 1998, 72, 4737.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number		10/045,292	
		Filing Date		18 October 2001	
		First Named Inventor		Stuyver, L.J. et al	
		Group Art Unit			
Sheet 2 of 3		Attorney Docket Number		08841.105024	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/	BA	NIEDBALLA, U. et al. <u>J. Org. Chem.</u> , 1976, 41, 2084	
/	BB	OZOLS, A. M. et al. <u>Synthesis</u> , 1980, 557.	
/	BC	PANKIEWICZ, K. W. et al., <u>Carbohydr. Res.</u> , 1984, 127, 227.	
/	BD	PANKIEWICZ, K. W. et al., <u>Nucleosides & Nucleotides</u> , 1991, 10, 1333.	
/	BE	ROBERTS, M. et al. <u>J. Am. Chem. Soc.</u> , 1952, 74, 668.	
/	BF	SERGUEEVA, Z. A. et al. <u>Nucleosides Nucleotides Nucleic Acids</u> , 2000, 19, 275.	
/	BG	SHI et al., <u>J. Med. Chem.</u> , 1999, 42, 859.	
/	BH	STAVBER, S. et al. <u>J. Chem. Soc. Chem. Commun.</u> , 1983, 563.	
/	BI	SUHADOLNIK, R. J. et al. <u>Carbohydr. Res.</u> , 1978, 61, 545.	
/	BG	TANAKA, H. et al. <u>Chem. Pharm. Bull.</u> , 1983, 31, 787.	
/	BH	TANAKA, H. et al. <u>Tetrahedron Lett.</u> , 1979, 4755.	
/	BI	THURBER, T. C. et al. <u>J. Am. Chem. Soc.</u> , 1973, 95, 3081.	
/	BJ	THURBER, T.C. et al. <u>J. Org. Chem.</u> , 1976, 41, 1041.	
/	BK	TOWNSEND, L. B. et al. <u>Nucleic Acid Chem.</u> , 1978, 1, 272 and 343.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/045,292
				Filing Date	18 October 2001
				First Named Inventor	Stuyver, L.J. et al
				Group Art Unit	
Sheet	3	of	3	Attorney Docket Number	08841.105024

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/	CA	VORBRUGGEN, H. et al. <u>Chem. Ber.</u> , 1981, 114, 1234.	
/	CB	WALTON, E. et al. <u>J. Am. Chem. Soc.</u> , 1964, 86, 2952.	
/	CC	WATANABE, "The Chemistry of C-Nucleosides", TOWNSEND, L. B., Ed., In <u>"Chemistry of Nucleosides and Nucleotides"</u> , Plenum Publ., New York, Vol., 3, 421, 1994	

2323214

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.